Drugs / VT301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05016427 | Nov 2020 → Nov 2021 | Alzheimer disease | VTBIO Co. LTD | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VT301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05016427 ↗ |
| Known as | Aβ-hTreg | “dose-limiting toxicity was experienced by none of the participants within five days of receiving GMP-grade Aβ-hTreg (VT301), indicating its good tolerability.” PMID 39626378 ↗ Dec 2024 |
| Modality | Cell therapy | “ex vivo-expanded amyloid beta-specific human regulatory T cells” PMID 39626378 ↗ Dec 2024 |